Slovenian pharmaceutical leader Krka has marked a standout year in 2024, reporting a 13% rise in net profit to €353.4 million and achieving record revenues of €1.91 billion, up 6% from the previous year.
The company’s growth has been fueled by robust performance across its key markets, particularly in East Europe, where it captured 34.2% of its revenue.
The majority of Krka’s revenue—82.5%—comes from prescription medicines, while over 22 new product approvals cemented its growing influence.
With a solid focus on production innovation, Krka invested €117 million in 2024 to enhance technology and quality, setting the stage for further growth.
As it looks toward 2025, the company anticipates a new milestone: revenues of €2 billion and profits of €365 million, a solid leap beyond original projections.
Expanding its workforce of 12,810 employees globally, Krka continues to strengthen its position as a European pharma powerhouse.
